Search research articles
Contact Us
Filters
Showing results (121-130 of 129) with videos related to
Page
of 13
Sort By:
You have reached the last page of results.
This site can display upto 129 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 17, 2023
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels
K T Helzer, M N Sharifi, J M Sperger, et al.
Journal of Medicinal Chemistry
|
August 18, 2017
Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates
Antonia F Stepan, Michelle M Claffey, Matthew R Reese, et al.
Cancer Discovery
|
April 1, 2025
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Marina N Sharifi, Jamie M Sperger, Amy K Taylor, et al.
Cancer Discovery
|
February 6, 2025
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes
Marina N Sharifi, Jamie M Sperger, Amy K Taylor, et al.
Science (New York, N.Y.)
|
November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19
Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Biorxiv : the Preprint Server for Biology
|
September 16, 2020
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Nature Communications
|
October 19, 2021
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Journal of Medicinal Chemistry
|
April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry
|
February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease
Jamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Page
of 13
Search research articles
Search
Showing results (121-130 of 129) with videos related to
Sort By:
Page
of 13
You have reached the last page of results.
This site can display upto 129 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 17, 2023
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels
K T Helzer, M N Sharifi, J M Sperger, et al.
Journal of Medicinal Chemistry
|
August 18, 2017
Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates
Antonia F Stepan, Michelle M Claffey, Matthew R Reese, et al.
Cancer Discovery
|
April 1, 2025
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Marina N Sharifi, Jamie M Sperger, Amy K Taylor, et al.
Cancer Discovery
|
February 6, 2025
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes
Marina N Sharifi, Jamie M Sperger, Amy K Taylor, et al.
Science (New York, N.Y.)
|
November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19
Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Biorxiv : the Preprint Server for Biology
|
September 16, 2020
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Nature Communications
|
October 19, 2021
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Britton Boras, Rhys M Jones, Brandon J Anson, et al.
Journal of Medicinal Chemistry
|
April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry
|
February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease
Jamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Page
of 13